P
Petr Jansky
Researcher at Charles University in Prague
Publications - 78
Citations - 14291
Petr Jansky is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Atrial fibrillation & Stroke. The author has an hindex of 22, co-authored 57 publications receiving 12793 citations. Previous affiliations of Petr Jansky include McMaster University & Population Health Research Institute.
Papers
More filters
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Journal ArticleDOI
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
John H. Alexander,Renato D. Lopes,Stefan James,Rakhi Kilaru,Yaohua He,Puneet Mohan,Deepak L. Bhatt,Shaun G. Goodman,Freek W.A. Verheugt,Marcus Flather,Kurt Huber,Danny Liaw,Steen Elkjær Husted,Jose Lopez-Sendon,Raffaele De Caterina,Petr Jansky,Harald Darius,Dragos Vinereanu,Jan H. Cornel,Frank Cools,Dan Atar,Jose L. Leiva-Pons,Matyas Keltai,Hisao Ogawa,Prem Pais,Alexander Parkhomenko,Witold Rużyłło,Rafael Diaz,Harvey D. White,Mikhail Ruda,Margarida Geraldes,Jack Lawrence,Robert A. Harrington,Lars Wallentin +33 more
TL;DR: The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events as mentioned in this paper.
Journal ArticleDOI
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Salim Yusuf,Jackie Bosch,Gilles R. Dagenais,Jun Zhu,Denis Xavier,Lisheng Liu,Prem Pais,Patricio Lopez-Jaramillo,Lawrence A. Leiter,Antonio L. Dans,Alvaro Avezum,Leopoldo S. Piegas,Alexander Parkhomenko,Katalin Keltai,Matyas Keltai,Karen Sliwa,Ron J.G. Peters,Claes Held,Irina Chazova,Khalid Yusoff,Basil S. Lewis,Petr Jansky,Kamlesh Khunti,William D. Toff,Christopher M. Reid,Christopher M. Reid,John Varigos,Gregorio Sanchez-Vallejo,Robert S. McKelvie,Janice Pogue,Hyejung Jung,Peggy Gao,Rafael Diaz,Eva Lonn,Hope Investigators +34 more
TL;DR: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease.
Journal ArticleDOI
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Eva Lonn,Eva Lonn,Jackie Bosch,Jackie Bosch,Patricio Lopez-Jaramillo,Jun Zhu,Lisheng Liu,Prem Pais,Rafael Diaz,Denis Xavier,Karen Sliwa,Antonio L. Dans,Alvaro Avezum,Leopoldo S. Piegas,Katalin Keltai,Matyas Keltai,Irina Chazova,Ron J.G. Peters,Claes Held,Khalid Yusoff,Basil S. Lewis,Petr Jansky,Petr Jansky,Alexander Parkhomenko,Kamlesh Khunti,William D. Toff,William D. Toff,Christopher M. Reid,Christopher M. Reid,John Varigos,Lawrence A. Leiter,Dora I. Molina,Robert S. McKelvie,Robert S. McKelvie,Janice Pogue,Joanne Wilkinson,Hyejung Jung,Gilles R. Dagenais,Salim Yusuf,Salim Yusuf +39 more
TL;DR: Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a doses of 12.5mg per day was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease.